|What is biopharmaceutical industry doing with Key Account Management across Europe?|
|The Cegedim RM Key Account Management best practices survey explores the Life Sciences KAM trends|
|In parternership with:
|1. Do you represent an affiliate or an HQ organization?
2. Where are you based?
3. What is your current position?
4. Which of the following describes your organization’s
involvement in KAM? (one answer only)
5. In which of the following customer environments
do you implement KAM? (several answers possible)
6. Which of the following benefits are you expecting
from KAM? (several answers possible)
7. As you have attempted to implement KAM, which of the following topics
have proved to be challenges?
If you are only starting implementation, then which do you anticipate being challenges?
8. When considering tools and data to support KAM initiatives,
how do you value the following attributes?
9. UK respondents only: Do you believe that the UK Government’s proposed changes
to the NHS will have a significant impact on your KAM Strategy ?
10. UK respondents only. From what you know of the proposed changes
to the NHS, how do you expect the level of KAM resource to be impacted?